GlassScriptPhysician profile
Kelly Bhatt
NPI 1336712603
$5,517.30
in general payments reported to CMS, 2019-2025
31 companies · $794 in 2025
The $794 reported for 2025 was more than what 81% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $107 · 2022: $1,159 · 2023: $1,010 · 2024: $2,447 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,681 · Travel and Lodging: $427 · Education: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,680.71 |
| Travel and Lodging | $426.93 |
| Education | $144.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $954.83 | 2022-2025 | |
| Boston Scientific Corporation | $775.41 | 2024-2025 | Watchman Flx |
| Medtronic, INC. | $437.80 | 2021-2024 | Selectsecure, Micra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $431.54 | 2021-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $406.23 | 2022-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $404.20 | 2022-2025 | Verquvo, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $287.85 | 2021-2025 | Lokelma, Farxiga |
| Amgen INC. | $263.52 | 2022-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $204.53 | 2022-2025 | Eliquis, Camzyos |
| Pfizer INC. | $193.71 | 2022-2025 | |
| Heartflow, INC. | $173.19 | 2022-2024 | |
| Daiichi Sankyo INC. | $130.21 | 2023-2024 | Injectafer |
| Novo Nordisk INC | $121.83 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $115.89 | 2022-2024 | |
| Kiniksa Pharmaceuticals, LTD. | $106.94 | 2023 | Arcalyst |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $55.58 | 2023-2024 | Nexletol |
| Regeneron Healthcare Solutions, INC. | $50.34 | 2023-2024 | Evkeeza |
| Lexicon Pharmaceuticals, INC. | $49.93 | 2024 | |
| Amarin Pharma, INC. | $49.51 | 2022 | |
| Alnylam Pharmaceuticals INC. | $44.39 | 2024 | Amvuttra |
| Medicomp INC | $42.22 | 2023-2024 | Telepatch Cardiac Monitor |
| Cvrx, INC. | $33.82 | 2024 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $32.70 | 2023-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $22.44 | 2021 | |
| Atricure, INC. | $22.27 | 2024 | |
| Astellas Pharma US INC | $19.84 | 2022 | |
| Tactile Systems Technology INC | $19.73 | 2023 | Flexitouch Plus, Entre Plus |
| Kiniksa Pharmaceuticals International, Plc | $19.06 | 2024 | Arcalyst |
| Abiomed | $17.93 | 2023 | Impella |
| Philips North America LLC | $15.34 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Bhatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.